Solid Biosciences
Advance the development of its novel gene therapy platform.
Launch date
Employees
Market cap
$298m
Enterprise valuation
$133m (Public information from Sep 2024)
Share price
$7.86 SLDB
Boston Massachusetts (HQ)
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | - | 13.6m | 8.1m | - | 3.6m | <1m | 3.1m |
% growth | - | - | (41 %) | - | - | (90 %) | 749 % |
EBITDA | (80.6m) | (69.3m) | (108m) | (102m) | (98.6m) | (119m) | (83.9m) |
% EBITDA margin | - | (509 %) | (1333 %) | - | (2721 %) | (32135 %) | (2672 %) |
Profit | (88.3m) | (72.2m) | (86.0m) | (96.0m) | (106m) | (126m) | (157m) |
% profit margin | - | (530 %) | (1062 %) | - | (2921 %) | (34108 %) | (4994 %) |
EV / revenue | - | 5.4x | -13.4x | - | 56.9x | 593.5x | 77.5x |
EV / EBITDA | -4.3x | -1.1x | 1.0x | - | -2.1x | -1.9x | -2.9x |
R&D budget | 64.9m | 58.7m | 78.4m | 76.6m | - | - | - |
R&D % of revenue | - | 431 % | 969 % | - | - | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | N/A | Seed | |
$42.5m | Series B | ||
$50.0m | Series C | ||
N/A | N/A | IPO | |
* | $60.0m | Private Placement VC | |
$40.0m | Post IPO Equity | ||
* | N/A | $144m | Post IPO Equity |
* | $75.0m | Post IPO Equity | |
* | $109m | Private Placement VC | |
Total Funding | $261m |
Recent News about Solid Biosciences
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Solid Biosciences
EditACQUISITION by Solid Biosciences Sep 2022